Zeynep Busra Zengin

Zeynep Busra Zengin is a researcher at the Yale School of Medicine, Department of Medicine. Her work focuses on oncology, particularly renal cell carcinoma and urothelial cancers. She has contributed to studies on immune checkpoint inhibitors, microbiome impacts on cancer therapy, and clinical trial design. Zengin holds a Merit Award from the American Society of Clinical Oncology (2022) and a Travel Grant from the European Society of Medical Oncology (2021). Her recent research includes phase I trials evaluating combination therapies and the role of dietary modifications in metastatic RCC patients.

• Education: MD from Ankara Yildirim Beyazit University, Department of Medicine (2019)
• Postdoctoral Training: City of Hope Comprehensive Cancer Center (2023)

Research Interests: Her work bridges oncology and immunology, emphasizing translational research in renal malignancies. Key areas include circulating tumor DNA monitoring, microbiome modulation effects on immunotherapy response, and clinical outcomes of variant histology RCC.

Publications: Over 20 peer-reviewed articles since 2023, with recent focus on combination therapies (e.g., cabozantinib/nivolumab), microbiome-driven treatment strategies, and disparities in clinical trial access.

• Awards:
  • Merit Award - ASCO (2022)
  • Merit Award - ASCO Genitourinary Symposium (2022)
  • Travel Grant - ESMO (2021)
• Advisory Roles: Member of the Trainee & Early Career Advisory Group (2022–present)